abstract |
ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2B AND nMETHODSOFUSE nABSTRACT nProvided are antibodies and antigen-binding fragments thereof that band specifically to nhuman complement factor C2 and are capable of inhibiting activation of the classical and lectin npathways of the complement system. The antibodies and antigen-binding facment exhibit nimproved amnufacturability, pharmacokinetics, and antigen sweeping. Also provided are npharmaceutical compositions comprising the antiobodies and antigen-binding fragments, nucleic nacids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising nthe nucleic acids or vectors, and methods of making and using the antibodies and antigennbinding fragments. The antibodies and antigen-binding fragments can be used to inhibit the nclassical pathway of complement activation in a subject, e.g., a human. The antibodies and nantigen-binding fragments can also be used to inhibit the lectin pathway of complement nactivation in a subject, e.g., a human. |